771579-27-2

Basic information

• Product Name: 2(1H)-Pyridinone, 3-(aminomethyl)-4,6-dimethyl- (9CI)
• Synonyms: 2(1H)-Pyridinone, 3-(aminomethyl)-4,6-dimethyl- (9CI);3-(AMinoMethyl)-4,6-diMethyl-1,2-dihydropyridine-2-one;2(1H)-Pyridinone,3-(aMinoMethyl)-4,6-diMethyl-,hydrochloride(1:1);2(1H)-Pyridinone,3-(aMinoMethyl)-4,6-diMethyl-;3-(AMinoMethyl)-4,6-diMethyl-1,2-dihydropyridin-2-one;3-(Aminomethyl)-4,6-dimethyl-2(1H)-pyridinone;3-(aminomethyl)-4,6-dimethyl-1H-pyridin-2-one;N-BUTYL-2-CHLOROISONICOTINAMIDE
• CAS NO: 771579-27-2
• Molecular Formula: C₈H₁₂N₂O
• Molecular Weight: 152.19368
• Product Categories: METHYL;ALCOHOL
• Mol File: 771579-27-2.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 348.1±34.0 °C(Predicted)
• Appearance: /
• Density: 1.054±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 12.40±0.10(Predicted)
• CAS DataBase Reference: 2(1H)-Pyridinone, 3-(aminomethyl)-4,6-dimethyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Pyridinone, 3-(aminomethyl)-4,6-dimethyl- (9CI)(771579-27-2)
• EPA Substance Registry System: 2(1H)-Pyridinone, 3-(aminomethyl)-4,6-dimethyl- (9CI)(771579-27-2)

Safety Data

• Hazardous Substances Data: 771579-27-2(Hazardous Substances Data)

Usage

General Description

2(1H)-Pyridinone, 3-(aminomethyl)-4,6-dimethyl- (9CI) is a chemical compound with the molecular formula C9H11N3O. It is a derivative of pyridine and is commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs and biologically active compounds. This chemical is known for its antimicrobial, antifungal, and anti-inflammatory properties. It may also have potential applications in the development of new therapeutic agents for the treatment of various diseases and conditions. Additionally, it is important to handle this chemical with caution as it may pose health risks if not used properly and in accordance with safety regulations.

Upstream product

• 123-54-6 acetylacetone 
• 769-28-8 3-Cyano-4,6-dimethyl-2(1H)-pyridon 
• 769-28-8 2-hydroxy-4,6-dimethyl-3-carbonitrile 

Downstream Products

• 1396775-88-4 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-(hydroxymethyl)phenyl)-1-isopropyl-1H-pyrazolo[3,4-b]pyridine-4-carboxamide 
• 1396770-90-3 1-(1-benzylpiperidin-4-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide 
• 1396770-40-3 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(4-(piperazin-1-yl)phenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide 
• 1396770-44-7 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide 
• 1396771-63-3 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-(1-phenylethyl)-6-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide 
• 1354821-72-9 N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-4-carboxamide 
• 1396770-63-0 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(4-(4-methylpiperazine-1-carbonyl)phenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide 
• 1396770-68-5 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-((3-(dimethylamino)propyl)carbamoyl)phenyl)-1-isopropyl-1H-pyrazolo[3,4-b]pyridine-4-carboxamide 
• 1396770-73-2 6-(4-(aminomethyl)phenyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-pyrazolo[3,4-b]pyridine-4-carboxamide 
• 1396770-76-5 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-(((3-(dimethylamino)propyl)(methyl)amino)methyl)phenyl)-1-isopropyl-1H-pyrazolo[3,4-b]pyridine-4-carboxamide 
• 1396770-81-2 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-(((3-(dimethylamino)propyl)(methyl)amino)methyl)phenyl)-1-isopropyl-1H-pyrazolo[3,4-b]pyridine-4-carboxamide 
• 1396772-26-1 1-cyclopentyl-N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]-1H-indazole-4-carboxamide 
• 1396772-66-9 1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-(3-(methylamino)propoxy)phenyl)-1H-indazole-4-carboxamide 
• 1396772-71-6 1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-(3-(dimethylamino)propoxy)phenyl)-1H-indazole-4-carboxamide 

Relevant articles and documents

Small molecule compound based on EZH2 protein degradation, and application thereof

The invention discloses a series of small molecule compounds capable of selectively degrading EZH2 protein, and application thereof. The compounds can be prepared into proper pharmaceutical dosage forms for EZH2-mediated related tumor treatment.

Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma

Traditional EZH2 inhibitors are developed to suppress the enzymatic methylation activity, and they may have therapeutic limitations due to the nonenzymatic functions of EZH2 in cancer development. Here, we report proteolysis-target chimera (PROTAC)-based EZH2 degraders to target the whole EZH2 in lymphoma. Two series of EZH2 degraders were designed and synthesized to hijack E3 ligase systems containing either von Hippel-Lindau (VHL) or cereblon (CRBN), and some VHL-based compounds were able to mediate EZH2 degradation. Two best degraders, YM181 and YM281, induced robust cell viability inhibition in diffuse large B-cell lymphoma (DLBCL) and other subtypes of lymphomas, outperforming a clinically used EZH2 inhibitor EPZ6438 (tazemetostat) that was only effective against DLBCL. The EZH2 degraders displayed promising antitumor activities in lymphoma xenografts and patient-derived primary lymphoma cells. Our study demonstrates that EZH2 degraders have better therapeutic activity than EZH2 inhibitors, which may provide a potential anticancer strategy to treat lymphoma.

1,5,7-TRISUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES

The present disclosure relates to 1,5,7-trisubstituted isoquinoline derivatives, their preparation and pharmaceutical use. In particular, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. The definitions of the groups in the formula can be found in the specification and claims.